drugset
drugset / Trial / NCT00694642

Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis

NCT00694642 ↗

Phase 1/2 Completed 28 enrolled Pilar Jimenez Quevedo Fundación Mutua Madrileña · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether transendocardial injections of autologous endothelial progenitor cells CD 133 is safe and feasible in patients with refractory angina.

Timeline

Start
2008-05
Primary completion
2009-05
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Selected CD 133+ cells Cell therapy — Other

Indications

coronary artery disorder